Early trial of new drug shows promise for patients with triple-negative breast cancer

Early trial of new drug shows promise for patients with triple-negative breast cancer
Study author Dr. Rita Nanda meets with a triple-negative breast cancer patient in clinic at the University of Chicago Medicine. Credit: The University of Chicago Medicine

In patients with metastatic triple-negative breast cancer—a disease with no approved targeted therapies—infusion of pembrolizumab produced durable responses in almost one out of five patients enrolled in a phase-Ib clinical trial, according to data presented Dec. 10, at the 2014 San Antonio Breast Cancer Symposium.

The multi-center, non-randomized trial was designed to evaluate the safety, tolerability and of bi-weekly infusions of pembrolizumab (MK-3475, marketed as Keytruda®). The researchers enrolled 27 , aged 29 to 72 years, who had metastatic that either relapsed after treatment for early stage disease or progressed on therapy for advanced disease.

"For this group of patients our are limited to chemotherapy," said study director Rita Nanda, MD, assistant professor of medicine and associate director of the breast medical oncology program at the University of Chicago.

All patients in the study had triple-negative tumors with high levels of a protein called programmed death-ligand 1 (PD-L1). This protein can suppress the immune system's efforts to eliminate . Pembrolizumab is a monoclonal antibody designed to help reactivate a person's own immune system to help fight the tumor.

"Pembrolizumab appears to make a significant difference for a subset of patients," Nanda said. "Of the 27 patients in this study with measurable disease, five (18.5%) had encouraging results. One patient had a complete response, and four had a partial response to treatment."

Responses for those five patients were long-lasting. Meanwhile, the patient with a complete response and two of those with a partial response continue to be treated with pembrolizumab.

An additional seven patients had stable disease, and twelve had progressive disease. Three patients left the trial early because their disease progressed.

Pembrolizumab, approved in September 2014 by the Food and Drug Administration for treatment of melanoma, does have some side effects. But Nanda said those are generally mild and easy to manage. They include fatigue, cough, nausea, itchy skin, rash, decreased appetite, constipation, joint pain and diarrhea.

In this trial, four of the 27 patients experienced at least one severe or life-threatening drug-related adverse event. One patient died while on the study treatment.

"The median survival for patients with triple-negative breast cancer is approximately one year," Nanda said. "We need better treatments for this disease. The promising activity of pembrolizumab seen in PD-L1-expressing, triple-negative is exciting, and certainly worthy of further investigation."

An important next step, she said, is to learn how to predict which patients are most likely to benefit and how to manage the drug's toxicity.

An earlier study of pembrolizumab, presented in June at the annual meeting of the American Society of Clinical Oncology by Tanguy Seiwert, MD, assistant professor of medicine at the University of Chicago, found a similar response rate in PD-L1 positive patients with advanced head and neck cancer.


Explore further

Studies show immunotherapy drugs improve outcomes in Hodgkin lymphoma patients

Provided by University of Chicago Medical Center
Citation: Early trial of new drug shows promise for patients with triple-negative breast cancer (2014, December 10) retrieved 15 February 2019 from https://medicalxpress.com/news/2014-12-early-trial-drug-patients-triple-negative.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more